Skip to content
The Nexus
DossierENTITY

Amarin

Coverage of Amarin in the Nexus archive.

Earliest in view: Jun 4 · 18:04 UTCMost recent: Jun 4 · 18:04 UTC
Co-mentioned in this coverage
Hikma Pharmaceuticalsorganization1Supreme Courtorganization1skinny labelingtopic1
Recent coverage
  • HEALTHJun 4 · 18:04 UTCSTAT NEWS
    STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case

    The Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe on Amarin's patents, supporting the use of 'skinny labeling' by generic drugmakers. This decision overturns a lower court ruling and reduces legal risks for generic companies marketing drugs for specific uses to avoid patent infringement lawsuits.